trial

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

NCTId NCT02202213
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 47 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2015-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
47 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2013-10
Primary completion
2015-02
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Lu AF11167

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
47
Phase
PHASE1
Primary Completion Date
2015-02
Status
COMPLETED
relationships
The graph out of here
drug
Lu AF11167
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication